University of Caen-Normandie Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Caen France (1432)

Organization Overview

First Clinical Trial
2003
NCT01070862
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Anesthesiologist | Baclesse, Caen, France | Caen (FR), University College Hospital | Caen Hospital | Caen University Hospital, Normandie UNIV, UNICAEN, PSL Research University, EPHE, Inserm, U1077, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine, 14000 Caen, France | Centre François Baclesse | Centre Francois Baclesse | Centre François Baclesse | Centre Francois Baclesse-CAEN | Centre François Baclesse, Caen, France | Centre Francois Baclesse, Luxembourg | Centre Hospitalier Universitaire CAEN | Centre Hospitalier universitaire de Caen | Centre Hospitalier Universitaire de Caen Normandie | CHRU Caen | CHRU de Caen | CHU caen | CHU Caen | CHU CAEN | CHU Cote de Nacre, Caen, France | Endocrinology Unit, University Hospital of Caen, FRANCE | GELA - CHU de Caen, Caen, FR | Hopital Cote de Nacre, Caen | Hopital Cote de Nacre CAEN France | HOSPITAL, CAEN | Université de Caen Normandie | University Hospital, Caen | University hospital of Caen | University Hospital of Caen | Universtiy Hospital of Caen

Active Ingredients

Drugs in Phase 4 Trials (14)

adalimumab (humira) (1 trial)

amiodarone (cordarone) (1 trial)

cangrelor (kengreal) (1 trial)

colchicine (colbenemid) (1 trial)

epoetin (Epogen) (1 trial)

follitropin alfa (Gonal-F) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

iron (1 trial)

landiolol (2 trials)

lidocaine (xylocaine) (3 trials)

nevirapine (viramune) (1 trial)

prednisone (meticorten) (4 trials)

rasagiline (azilect) (1 trial)

sitagliptin (januvia) (1 trial)

Drugs in Phase 3 Trials (47)

alteplase (Activase) (2 trials)

anakinra (Kineret) (1 trial)

autologous adipose-derived mesenchymal stem cells (2 trials)

autologous skeletal myoblast (1 trial)

bevacizumab (avastin) (4 trials)

bleomycin (blenoxane) (1 trial)

bortezomib (velcade) (1 trial)

calcifediol (1 trial)

carboplatin (paraplatin) (7 trials)

cisplatin (platinol) (3 trials)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (2 trials)

dacarbazine (dtic-dome) (1 trial)

dostarlimab (Jemperli) (1 trial)

doxorubicin (Doxil) (2 trials)

emtricitabine (emtriva) (3 trials)

erlotinib (tarceva) (1 trial)

esomeprazole (nexium) (1 trial)

estradiol (progynon depot) (1 trial)

etoposide (vepesid) (4 trials)

exenatide (byetta) (1 trial)

fludeoxyglucose f-18 (4 trials)

fluorouracil (efudex) (3 trials)

hyaluronic acid (1 trial)

hydroxyethyl starch (voluven) (1 trial)

melphalan (alkeran) (3 trials)

memantine (namenda) (1 trial)

metronidazole (flagyl) (1 trial)

misoprostol (cytotec) (1 trial)

nicotinamide (1 trial)

paclitaxel (taxol) (3 trials)

pemetrexed (alimta) (2 trials)

procaine benzylpenicillin (novocaine) (1 trial)

procarbazine (matulane) (1 trial)

red blood cells (2 trials)

sargramostim (leukine) (2 trials)

sodium bicarbonate (1 trial)

sodium chloride (1 trial)

spironolactone (aldactone) (1 trial)

tenofovir (viread) (3 trials)

testosterone (delatestryl) (1 trial)

tetracycline (tetrex) (1 trial)

thalidomide (Thalomid) (1 trial)

urea (1 trial)

vinblastine (velban) (1 trial)

vincristine (oncovin) (3 trials)

vitamin d3 (2 trials)

Drugs in Phase 2 Trials (42)

acetylcysteine (mucomyst) (1 trial)

acetylsalicylic acid (aspirin) (1 trial)

atezolizumab (Tecentriq) (2 trials)

avelumab (bavencio) (1 trial)

bendamustine (treanda) (1 trial)

brentuximab vedotin (adcetris) (1 trial)

cabozantinib (cometriq) (1 trial)

cyclosporine (sandimmune) (1 trial)

cytarabine (cytosar-u) (1 trial)

daratumumab (darzalex) (1 trial)

diosmectite (Smecta) (1 trial)

doravirine (pifeltro) (1 trial)

essential oils (1 trial)

fluoromethylcholine (18f) (FCH) (1 trial)

fluoromisonidazole (1 trial)

gemcitabine (gemzar) (1 trial)

ixazomib (ninlaro) (1 trial)

ketamine (ketalar) (1 trial)

lamivudine (epivir) (1 trial)

lanreotide (somatuline depot) (1 trial)

lapatinib (tykerb) (1 trial)

lenalidomide (revlimid) (1 trial)

leucovorin (1 trial)

loperamide (imodium) (1 trial)

mitomycin (mutamycin) (1 trial)

mitoxantrone (novantrone) (1 trial)

navitoclax (1 trial)

olaparib (lynparza) (1 trial)

oxaliplatin (eloxatin) (1 trial)

oxybutynin (ditropan) (1 trial)

panitumumab (vectibix) (1 trial)

ralimetinib (1 trial)

rilotumumab (1 trial)

rituximab (rituxan) (3 trials)

sodium fluoride (18F) (1 trial)

sorafenib (nexavar) (1 trial)

talazoparib (talzenna) (1 trial)

tamoxifen (nolvadex) (1 trial)

temozolomide (temodar) (1 trial)

topotecan (hycamtin) (1 trial)

trastuzumab (herceptin) (1 trial)

vinorelbine (navelbine) (2 trials)

Drugs in Phase 1 Trials (6)

allogeneic adipose derived mesenchymal stem cell (1 trial)

apixaban (eliquis) (1 trial)

bictegravir (Biktarvy) (1 trial)

daptomycin (cubicin) (2 trials)

fludarabine (fludara) (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

Drugs in Other Trials (16)

15o water (1 trial)

acetaminophen (tylenol) (1 trial)

aldosterone (1 trial)

aspartate (1 trial)

atracurium (tracurium) (1 trial)

fluorothymidine (1 trial)

ginseng (1 trial)

insulin human (humulin) (1 trial)

iobenguane (123i) (1 trial)

lactulose (cephulac) (1 trial)

levocarnitine (carnitor) (1 trial)

l-glutamine (1 trial)

morphine (1 trial)

oxygen (1 trial)

propofol (diprivan) (1 trial)

ropivacaine (naropin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Adenocarcinoma (Phase 2)

Adenoma (Phase 2)

Anemia, Iron-Deficiency (Phase 4)

Anus Neoplasms (Phase 2)

Arteritis (Phase 4)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Atrial Fibrillation (Phase 4)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Carotid Stenosis (Phase 2)

Chondrocalcinosis (Phase 4)

Cognition Disorders (Phase 3)

Crush Injuries (Phase 1)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Diarrhea (Phase 2)

Dyslipidemias (Phase 4)

Esophageal Neoplasms (Phase 2)

Facial Paralysis (Phase 4)

Facies (Phase 4)

Giant Cell Arteritis (Phase 4)

Glioma (Phase 2)

Graft vs Host Disease (Phase 2)

Head and Neck Neoplasms (Phase 3)

Hemorrhage (Phase 3)

Hodgkin Disease (Phase 3)

Hypercholesterolemia (Phase 4)

Hyperparathyroidism (Phase 2)

Hypogonadism (Phase 3)

Immunologic Deficiency Syndromes (Phase 4)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Medulloblastoma (Phase 2)

Melanoma (Phase 2)

Meningeal Carcinomatosis (Phase 2)

Meningitis (Phase 2)

Mesothelioma (Phase 3)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 3)

Muscular Dystrophies (Phase 3)

Muscular Dystrophy, Oculopharyngeal (Phase 3)

Nausea (Phase 2)

Neoplasm Metastasis (Phase 4)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Neutropenia (Phase 3)

Obesity, Morbid (Phase 3)

Osteoporosis (Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Parathyroid Neoplasms (Phase 2)

Paresis (Phase 4)

Parkinson Disease (Phase 4)

Polycystic Ovary Syndrome (Phase 4)

Polymyalgia Rheumatica (Phase 4)

Postpartum Hemorrhage (Phase 3)

Prolapse (Phase 3)

Prostatic Neoplasms (Phase 2)

Recurrence (Phase 2)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 1)

Retinal Neoplasms (Phase 2)

Retinoblastoma (Phase 2)

Sarcoma (Phase 2)

Sclerosis (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Stomach Neoplasms (Phase 2)

Stroke (Phase 2)

Subarachnoid Hemorrhage (Phase 3)

Syndrome (Phase 4)

Telangiectasia, Hereditary Hemorrhagic (Phase 2)

Telangiectasis (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Vomiting (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 99
  • # of Trial APIs: 125